Format

Send to

Choose Destination
Biomed Res Int. 2019 Aug 25;2019:8023541. doi: 10.1155/2019/8023541. eCollection 2019.

Potential Diagnostic and Prognostic Biomarkers of Circular RNAs for Lung Cancer in China.

Author information

1
Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China.
2
West China Medical School, Sichuan University, Chengdu, China.
3
Department of Targeted Tracer Research and Development Laboratory, West China Hospital, Sichuan University, Chengdu, China.
4
Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, China.
5
Clinic Skill Center, West China Hospital, Sichuan University, Chengdu, China.

Abstract

Emerging evidence demonstrated that circular RNAs (circRNAs) were dysregulated in lung cancer, indicating that circRNAs might serve as novel diagnostic and prognostic biomarkers for lung cancer. However, the clinical value of circRNAs on lung cancer remains unclear. This study aimed to evaluate the efficiency of circRNAs in the diagnosis and prognosis for lung cancer in China. 2122 Chinese individuals were enrolled in this investigation for assessment of diagnostic value and examination of prognostic analysis. In the diagnostic analysis, the pooled sensitivity, specificity, PLR, NLR, DOR, and AUC of the sROC curve with their 95% CIs were 0.80 (95%CI: 0.74-0.84), 0.80 (95%CI: 0.73-0.86), 3.97 (95%CI: 2.80-5.62) and 0.26 (95%CI: 0.19-0.34), 15.51 (95%CI: 8.76-24.47), and 0.85 (95%CI: 0.82-0.88), respectively. As for the prognostic power of circRNAs, lung cancer patients with higher expression levels of circRNAs tend to possess lower overall survival with the overall pooled HR (1.70, 95%CI: 1.26-2.29). Furthermore, in stratified analysis, upregulated and downregulated circRNAs were manifested to exert significant effects on prognosis with HR values of 2.17 (95%CI: 1.74-2.72) and 0.52 (95%CI: 0.34-0.80). This study validates that circRNAs are promising diagnostic and predictive biomarkers for lung cancer patients in China.

Conflict of interest statement

The authors have declared that no conflicts of interest exist.

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center